The Need for Innovative Care
Severe joint inflammation drastically alters the condition of patients on a day-to-day basis suffering from the direct and indirect effects of severe Rheumatoid Arthritis (RA). Chronic inflammation results in the daily struggle to remain mobile and introduces almost constant agonizing pain in the patient. This autoimmune condition irreparably damages affected synovial tissues and patients experience progressive physical deterioration and psychological suffering caused by the unending pain. A stem cell therapy offers patients the promise of even greater hope than the recent advances in regenerative medicine. There are a number of pharmaceutical approaches to the management of the condition, however, to date, none have addressed the fundamental underlying dysregulation of the immune system. During the past several years, numerous researchers have focused on umbilical cord derived mesenchymal stem cells (UC-MSCs) as a powerful and promising biological substrate for the modification of RA at its fundamental level. Transplanting these multipotent cells will provide a viable therapeutic option to address the underlying pathophysiology of the condition rather than the daily band-aid palliative measures afforded by conventional treatment options.
The Pathological Destructive Mechanism
To understand the complex mechanism of immune system dysregulation of the severe Rheumatoid Arthritis condition, it is necessary to view the autoimmune disorder from the cellular level. The immune system of a healthy individual is able to differentiate between attack and defense. In severe RA, a misidentification phenomenon occurs where macrophages and T cells become rogue and attack healthy cells. This cellular defense phenomenon is exacerbated by the release of proinflammatory cytokines, and in particular tumor necrosis factor alpha (TNF-α) which is released into joint spaces. As a result of the cellular defense phenomenon, synovial membranes begin to thicken abnormally and form pannus tissue This phenomenon causes severe stiffness and joint deformity. The constant inflammation leads to the breakdown and erosion of articular cartilage, requiring stem cell interventions like UC-MSCs.
Halting cytokine storms is only possible through advanced immunomodulation techniques utilizing stem cell interventions like UC-MSCs. Basic chemical interventions are insufficient as they fail to traverse the molecular cascades of the progressive joint deterioration in Rheumatoid Arthritis.
Conventional Therapeutic Approaches and Their Inherent Drawbacks
The current conventional treatment methods for Rheumatoid Arthritis are based on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) during the early stages. These methods have a strong emphasis on the reduction of pain and the temporary control of the acute inflammatory response. Corticosteroids are often used for rapid relief in crises of severe Rheumatoid Arthritis in order to provide mobility for the patient for a short time. Although these treatment methods are used widely, they are inadequate for many physiological reasons. Perhaps the most concerning of these is the fact that, after a period of time, the patient becomes dependent on the treatment and suffers from the side effects of the drug. Among the various effects, the patient becomes highly susceptible to toxicity and severe immuno-suppression, as well as bleeding and gastrointestinal problems. None of these treatment methods can restore the injured and disabled joints, which become permanently disabled when the articular cartilage is completely degenerated. Therefore, the medical field must develop new and innovative, regenerative treatments, such as stem cell therapy using UC-MSCs, that can surpass the extensive boundaries of the pharmaceutical industry.
Therapeutic Use of UC-MSCs for the Control of Inflammation
The focus on newer, innovative methods must move away from temporary, chemical treatments and focus on UC-MSCs. These possess strong immunomodulatory properties, and therefore, are extremely well-suited to target the destructive effects of Rheumatoid Arthritis. When these MSCs enter an inflamed joint, they have the ability to control the inflammation at the site of injury by the paracrine mechanisms of stem cell signaling, and release a variety of bioactive molecules and cytokines. Among the released cytokines, are IL-10, which play important anti-inflammatory and injury control roles, and which can also eliminate the destructive inflammatory factors that are present in the rheumatoid synovial fluid. These living biological factories interact directly with rogue immune cells, compelling macrophages to metamorphose into their peaceful phenotype. This reprogramming of cells is effective in preventing pannus formation and preserves the bone. Besides the halting of the autoimmune attack in Rheumatoid Arthritis, UC-MSCs also activate local chondrocytes and begin the repair of cartilage. UC-MSCs also stimulate the repair of the extracellular matrix and restore the joints. The integration of this stem cell therapy resets the immune balance and prevents a relapse of the condition.
Figure 1: Comparing Rheumatoid Arthritis treatment approaches
Progressive Future Trajectory Within The Thai Landscape
The region of Southeast Asia has been the recipient of numerous advances in medicine, and Thailand has led the region in the application of these techniques. The application of UC-MSCs in the treatment of Rheumatoid Arthritis in Thailand has great potential. The Thai medical facilities have a reputation for the implementation of strict regulations and a focus on the worldclass and cutting edge. Thailand has created a focus on regenerative medicine, and this has resulted in the establishment of a research and clinical practice ecosystem. The application of regenerative stem cell medicine in Thailand offers the highest quality of clinical practice and research. Thailand has a focus on the production of biological mediators, and this focus on research makes Thailand the leading location for people interested in the newest advances in the correction of immunological problems.
Comprehensive Overview Regarding Cellular Interventions
Rheumatoid Arthritis causes significant global problems. However, advances in regenerative medicine and immunomodulation with umbilical cord-derived mesenchymal stem cells (UC-MSCs) may provide breakthroughs in halting damaging autoimmune disease processes. These therapies may promote safe repair of damaged cartilage while attenuating autoimmune inflammation. With the growing clinical expertise in Thailand, these therapies are likely to be available soon in the accessible stem cell therapy market in Thailand, providing hope to many patients. This new cellular therapy may lead to long-term restoration of mobility and the end of chronic pain.